Aflac Incorporated (AFL) Presents at Morgan Stanley US Financials Conference 2026 Transcript

Aflac said its two-business model across Japan and the U.S. remains the core growth engine, with Japan still the largest segment. Management highlighted that post-pandemic earned premium growth had been negative, but new products launched over the past couple of years, including Tsumitasu, are intended to support renewed growth. The discussion was broadly constructive, but it was a conference Q&A rather than a fresh earnings or guidance update.

Analysis

The key second-order signal is that Aflac is trying to re-accelerate growth in a business model that has been valued primarily for stability, not expansion. If the new product cycle in Japan can sustain even low-single-digit premium growth, the market will likely re-rate the stock because the earnings mix shifts from balance-sheet conservatism to visible top-line momentum, which tends to compress the discount applied to mature insurers. That matters more than headline EPS: when growth returns in a low-rate environment, multiple expansion can do more work than incremental underwriting improvement.

Japan is the cleaner catalyst, but also the more fragile one. Asset-accumulation products tend to look attractive when households are still sitting on excess cash, yet the durability of the pickup depends on whether these policies are a one-time migration of savings or the start of a broader replacement cycle. If sales normalize after the initial launch burst, the bull case becomes a valuation story only; if persistency holds and cross-sell improves, the earnings tailwind can extend over multiple years.

The U.S. business is less exciting at first glance, but it may be the hidden defensive lever if Japan slows. In a higher-volatility labor market, payroll-deducted supplemental health products can be unusually resilient because distribution friction stays low and employer churn is sticky; that makes the segment a useful counterweight if Japanese sales momentum fades. The main risk is that investors extrapolate early product success too aggressively and ignore that insurance growth often decelerates sharply after the initial launch window, especially if competitors respond with richer guarantees or more aggressive distribution incentives.

Near term, the stock is likely to trade on confidence in execution rather than near-term earnings revisions. The setup favors gradual upside over the next 3-6 months, but the downside case is meaningful if product launch data disappoints or if capital return expectations crowd out actual organic growth. The asymmetry is best expressed through relative value rather than outright beta, because the core franchise should limit drawdowns even if the growth narrative stalls.

Key Decisions for Investors

• Go long AFL into the next 1-2 earnings/sales readout window if Japanese product traction remains visible; target a 10-15% upside on multiple expansion, with downside capped by the defensive franchise.
• Pair long AFL vs short a slower-growing U.S. life insurer with less visible product innovation; the trade should work if the market rewards re-acceleration over static capital return stories over the next 3-6 months.
• Buy AFL call spreads 3-6 months out to capture narrative-driven re-rating while limiting premium at risk; best if the thesis is that growth visibility, not earnings beats, is the primary catalyst.
• If subsequent channel checks show Japan sales normalizing or persistency weakening, cut exposure quickly: the growth premium could evaporate within one quarter even if reported earnings stay stable.
• Treat any post-event rally as a hold-not-chase unless there is evidence of broad-based repeat demand; the setup is better for staged accumulation than aggressive breakout buying.